Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

NVAX News and Commentary

Caps

How do you think NVAX will perform against the market?

Add Stock to CAPS Watchlist

All Players

304 Outperform
84 Underperform
 

All-Star Players

41 Outperform
14 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top NVAX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mmurray (< 20)
Submitted April 18, 2015

nvax is performing well

TMFEBCapital (43.98)
Submitted April 26, 2017

I'm so skeptical of its RSV-F vaccine following multiple setbacks, and can't bring myself to want to gamble and own this one for the wildcard chance of it working.

NVAX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about NVAX.

Recs

0
Member Avatar InvestYoung (65.59) Submitted: 9/1/2017 10:17:34 AM : Outperform Start Price: $1.07 NVAX Score: -2.12

It all comes down to whether the RSV vaccine can be released.

George Budwell writes, "Respiratory syncytial virus (RSV) is a common respiratory ailment that can, on occasion, pose a serious threat to both infants and elderly adults. Unfortunately, biopharma companies have so far been unable to produce an effective prophylactic treatment for RSV for either young children or older adults. And that's why the clinical-stage vaccine-maker Novavax may turn out to be a once-in-a-lifetime type of investing opportunity.

Novavax is presently attempting to development an F-protein nanoparticle RSV vaccine that can be administered in conjunction with seasonal flu shots in elderly patients, as well as a vaccine for pregnant mothers that can confer immunity to newborns during the first few months of their lives.

Like most experimental RSV treatments to date, though, things haven't exactly gone to according to plan. Last year, Novavax's late-stage trial for elderly adults went off the rails due to a mild RSV season -- at least according to the company. And the vaccine's midstage maternal data weren't overwhelmingly significant. Put simply, Novavax's high-value RSV vaccine -- that could be worth billions if approved -- appears to be a long shot at best at this stage.

On the flip side, if Novavax can indeed pull a proverbial rabbit out of its hat and push this vaccine across the finish line, the company's stock would undoubtedly appreciate in Amazon-like fashion from current levels. Novavax, after all, presently sports a market cap of $307 million, which is only a tiny sliver of the massive commercial opportunity presented by this unmet medical need.

So will Novavax soar? I'm gonna gamble that the answer is yes.

Recs

1
Member Avatar TMFEBCapital (43.98) Submitted: 4/26/2017 1:19:51 PM : Underperform Start Price: $0.83 NVAX Score: -22.75

I'm so skeptical of its RSV-F vaccine following multiple setbacks, and can't bring myself to want to gamble and own this one for the wildcard chance of it working.

Recs

0
Member Avatar TMFFlygal (99.13) Submitted: 10/31/2016 9:29:14 PM : Outperform Start Price: $1.51 NVAX Score: -48.46

Insider buying after failed phase 3 trial, trial is being rerun. Worth a gamble

Leaderboard

Find the members with the highest scoring picks in NVAX.

Score Leader

tempttempt

tempttempt (73.04) Score: +668.41

The Score Leader is the player with the highest score across all their picks in NVAX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
marksaal 69.24 4/28/2009 Underperform 1Y $3.11 -65.27% +203.78% +269.06 1 Comment
AGCAPS < 20 4/28/2009 8/11/2011 Underperform 5Y $3.11 -65.27% +203.78% +269.06 0 Comment
OverHeld < 20 4/27/2009 Underperform 5Y $2.80 -61.43% +201.43% +262.86 0 Comment
shortguru 97.82 4/29/2009 Underperform 5Y $2.93 -63.14% +198.35% +261.49 0 Comment
storystockshort 97.99 4/29/2009 Underperform 5Y $2.93 -63.14% +198.35% +261.49 0 Comment
2iQPureAlpha 91.05 4/29/2009 Underperform 5Y $2.93 -63.14% +198.35% +261.49 0 Comment
DerSquirrel 77.60 4/29/2009 6/3/2011 Underperform 5Y $2.93 -63.14% +198.35% +261.49 0 Comment
examinebeyond 29.19 4/29/2009 Underperform 3W $2.93 -63.14% +198.35% +261.49 0 Comment
manetheren86 < 20 4/29/2009 Underperform 3M $2.95 -63.39% +192.60% +255.99 0 Comment
blue08 < 20 4/30/2009 Underperform 3W $2.89 -62.63% +191.41% +254.04 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.97 8/30/2016 Outperform 3W $6.96 -84.48% +17.19% -101.67 0 Comment
TrackJimCramer 84.97 6/3/2016 Underperform 3W $6.12 +13.73% +3.67% -10.05 8/30/2016 @ $6.96 0 Comment
TrackJimCramer 84.97 8/12/2015 Outperform 3W $13.65 -55.16% +0.69% -55.86 6/3/2016 @ $6.12 0 Comment
TrackJimCramer 84.97 3/12/2015 Underperform 3W $9.29 +46.93% +0.84% -46.10 8/12/2015 @ $13.65 0 Comment
TrackJimCramer 84.97 1/15/2015 Outperform 3W $6.20 +49.84% +4.06% +45.78 3/12/2015 @ $9.29 0 Comment
TrackUltraLong < 20 4/29/2013 Underperform NS $2.45 -55.92% +61.01% +116.93 1 Comment
TrackPoisedTo < 20 7/13/2012 Underperform 5Y $2.03 -46.80% +90.85% +137.65 0 Comment
TrackWedbush 86.95 3/15/2011 Outperform NS $2.64 -59.09% +101.81% -160.90 0 Comment
TrackDawsonJames < 20 6/16/2010 Outperform NS $2.29 -52.84% +129.29% -182.12 0 Comment
TrackRothCapital 71.94 3/15/2010 Outperform NS $2.45 -1.43% +17.47% -18.90 5/3/2011 @ $2.42 0 Comment
trackglobalhunte < 20 12/3/2009 Outperform NS $3.55 -69.58% +129.02% -198.60 0 Comment
TrackPiperJaff 87.02 12/2/2009 Outperform NS $3.14 -65.61% +130.32% -195.92 0 Comment
trackmerriman 73.78 11/5/2009 Outperform NS $3.92 -72.45% +141.78% -214.23 0 Comment
TrackOppenheimer 67.70 10/31/2007 Outperform NS $3.80 +61.84% -35.04% +96.89 9/2/2009 @ $6.15 0 Comment
TrackJimCramer 84.97 3/1/2006 Underperform 3W $5.69 +8.96% +53.49% +44.53 1/15/2015 @ $6.20 0 Comment

Featured Broker Partners